Arm Activity Measure (ArmA): Psychometric Evaluation of the Swedish Version

Therese Ramström (✉ therese.ramstrom@vgregion.se)
University of Gothenburg Institute of Clinical Sciences: Goteborgs universitet Institutionen for kliniska vetenskaper  https://orcid.org/0000-0003-0893-6615

Lina Bunketorp-Käll
University of Gothenburg Institute of Neuroscience and Physiology: Goteborgs universitet Institutionen for neurovetenskap och fysiologi

Johanna Wangdell
University of Gothenburg Institute of Clinical Sciences: Goteborgs universitet Institutionen for kliniska vetenskaper

Research

Keywords: CNS, SCI, TBI, Psychometric

DOI: https://doi.org/10.21203/rs.3.rs-102566/v1

License: Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Spasticity after an injury to the central nervous system (CNS) can cause profound disability (1). The prevalence of spasticity differs among various diagnoses, depending on how it is defined. Spasticity is reported to be present in 80% of patients with spinal cord injury (SCI) (2, 3), 60% of patients with traumatic brain injury (TBI) (4), and 30% of patients with stroke (5, 6). The consequences of spasticity in the upper limb (UL) range from reduced grip control to a clenched fist and can prevent prehension and grasp, which are critical for independence in activities of daily living (ADLs) (7). Left untreated, spasticity can lead to severe contractures, deformity, pain, and involuntary movement and severely compromise occupational performance [3, 9–11]. Since being active is fundamentally important for all living beings, and participation in activities is necessary for human physical and mental wellbeing (8), disabling UL spasticity can have devastating consequences.

Introduction

Spasticity after an injury to the central nervous system (CNS) can cause profound disability (1). The prevalence of spasticity differs among various diagnoses, depending on how it is defined. Spasticity is reported to be present in 80% of patients with spinal cord injury (SCI) (2, 3), 60% of patients with traumatic brain injury (TBI) (4), and 30% of patients with stroke (5, 6). The consequences of spasticity in the upper limb (UL) range from reduced grip control to a clenched fist and can prevent prehension and grasp, which are critical for independence in activities of daily living (ADLs) (7). Left untreated, spasticity can lead to severe contractures, deformity, pain, and involuntary movement and severely compromise occupational performance [3, 9–11]. Since being active is fundamentally important for all living beings, and participation in activities is necessary for human physical and mental wellbeing (8), disabling UL spasticity can have devastating consequences.

Patients with disabling spasticity are a heterogeneous group, and treatment goals differ depending on the degree of neurological impairment. For patients with residual volitional motor function, treatment often focuses on restoring active functions, whereas for those with more severe motor impairment, it focuses on improving passive everyday functional tasks, such as personal care (e.g., hygiene, dressing) Thus, to capture improvements resulting from various spasticity treatments, the outcome measure must include both passive and active aspects of everyday life.

Various measures can be used to assess the effects of spasticity on body function (9–12), but very few encompass both passive and active functional aspects. Even though these two functional constructs should be treated as separate entities, both are important in patient management. The lack of a comprehensive measure that is sensitive to change in patients with disabling UL spasticity resulted in the development of the Arm Activity Measure (ArmA) (13). The ArmA has been carefully evaluated and is a valid, reliable and responsive self-report questionnaire for assessing real-life arm function after focal therapy intervention, and in particular spasticity interventions (14, 15). ArmA can be done by the patient or a caregiver. ArmA has been translated into Thai (16), but not into Swedish. For use in a Swedish context,
ArmA must be translated and cross-culturally adapted to ensure that the Swedish version is semantically and conceptually equivalent to the original version. In this study, our goal was to translate ArmA into Swedish and adapt it to a Swedish context. We also evaluated its reliability, validity, and responsiveness in a sample of Swedish-speaking patients with problematic UL spasticity after CNS injury.

Materials And Methods

Translation and adaptation of the ArmA to a Swedish context

The developers of ArmA gave us permission (by correspondence with the first author in August 2017) to translate it into Swedish with a forward-back-translation procedure. To achieve equivalence between the original version of ArmA and the Swedish version (ArmA-S), ArmA was translated and cross-culturally adapted to the Swedish language and context, using the Beaton guidelines for translation of self-report health questionnaires (17). The translation process is summarized in Figure 1 and is described in detail in the appendix 1.

Measures

The ArmA questionnaire:

The ArmA is a self-report questionnaire used to measure the difficulty of passive and active UL daily tasks, referred to as passive and active function, in patients with unilateral paresis. The original questionnaire (https://www.kcl.ac.uk/cicelysaunders/research/outcome/rehabilitation/arma) comprises an eight-item passive function subscale (section A) and a 13-item active function subscale (section B), and uses a five-point Likert scoring system, from 0 (no difficulty) to 4 (unable to do the task). The previously evaluated version, however, comprises a seven-item passive function subscale (section A) scored from 0 to 28 (14, 16). The respondent is asked to circle the most appropriate response (0–4). Section B covers both unimanual and bimanual activities. Some of the unimanual activities are mostly done with the dominant hand. In the written instructions for the original version of ArmA, the respondent is asked to take the following into account when selecting a response option: If the task is never done, but this has nothing to do with your arm, please score difficulty as 0 (no difficulty). The passive function subscale (section A) scores range from 0 (high function) to 32, and the active function subscale (section B) scores range from 0 (high function) to 52. The subscales are analysed separately and may not be combined into a single sum score. The original version of ArmA is reliable and valid in patients with UL spasticity due to stroke and TBI and in those with other neurological injuries (15).

Other measures:

To evaluate construct validity and responsiveness, we collected the following outcome measures at baseline and 3 months after spasticity-correcting surgery. UL spasticity was quantified with the modified Ashworth scale (MAS) (18). For analysis, MAS scores were summed to provide a ‘composite spasticity score’. The grasp and release test (GRT) was used to assess the patient's ability to manipulate objects
typically used in ADLs. In the GRT, the patient is asked to pick up, move, and release six objects of different sizes, weights, and textures using a palmar or lateral grasp (19). The disability of the arm, shoulder, and hand (DASH) self-rated questionnaire (items 1–21) was used to assess the patient’s ability to perform activities during the previous week (20). The first 21 items of DASH assess the difficulty of performing activities because of UL problems. Each activity item is scored 0 (no difficulty) to 5 (extreme difficulty). To achieve a score comparable to that of the ArmA questionnaire in the evaluation of construct validity, we used the same strategy as in the initial evaluation of ArmA, in which a total score was calculated for the summated active function items (items 1 to 21).

Participants

The study population consisted of patients with UL spasticity due to CNS injuries who were referred to Centre of Advanced Reconstruction of Extremities (CARE), Sahlgrenska University Hospital. The patients were consecutive recruited between September 2017 and April 2020. According to a treatment algorithm at CARE, patients were allocated to one of three treatment regimens—high-, low-, or non-functioning (HFR, LFR, NFR)—based on the patient’s remaining sensorimotor control in the UL and on cognitive ability. The treatment regimens are presented in a previous study (21), and a study describing the feasibility of the specific treatment algorithm and clinical outcomes has been submitted. The inclusion criteria for the treatment regimens are presented in Table 1. The exclusion criteria were age <18 years, inability to complete questionnaires because of language difficulties, or cognitive impairment and the absence of a caregiver or relative to complete the questionnaire.

Data collection and test-retest reliability procedure

All authors participated in data collection. For the test-retest reliability procedure, the questionnaire was sent by mail to be completed 1 week before a scheduled visit to the clinic for the re-test. Alternatively, the questionnaire was sent by mail, and once returned, it was sent again 1 week later. No specific treatment was given between the two evaluations. Responsiveness was testing done at the clinic the day before the spasticity-correcting surgery, and again 3 months after surgery. The 3-month follow-up was done at the clinic or by mail.

Data analyses

Demographic and clinical characteristics of the study population were analysed with descriptive statistics. In analysing the questionnaires we used the following approach: when patients gave 2 answers on the same question or put a mark between 2 answers, the worse outcome was recorded. Questionnaires with missing items were excluded.

Internal consistency reliability of the two ArmA sections was assessed with Cronbach’s alpha. A Cronbach’s alpha >0.80 was considered good, 0.80–0.70 was considered moderate, and <0.70 was considered low (22).
**Test-retest reliability** was evaluated with the quadratic weighted kappa. Kappa $\geq 0.70$ was considered to indicate good reproducibility (22, 23).

**Face and content validity** (relevance and adequacy of items for the intended use) was evaluated by letting a group of clinicians and experts in spasticity induced by CNS injury carefully review the prefinal version of ArmA-S. This version was also reviewed by 15 patients with UL spasticity due to SCI and stroke. After modifications, the final version of the ArmA-S was reviewed by 20 patients with spasticity induced by CNS injury, who also responded to written questions about the questionnaire's relevance and about the time it took and how difficulty it was to complete. The final version was also sent to 8 clinicians who work with patients with disabling UL spasticity to ask about their perceptions of the relevance and usefulness of the ArmA-S.

**The acceptability** of the questionnaire's response rate was assessed by computing the percentage of missing responses to survey questions, the distribution of scores, and the magnitude of ceiling and floor effects (i.e., proportion of best and worst possible scores, respectively). Floor and ceiling effects are considered to be present when more than 15% of the respondents reach the highest or lowest possible numeric value of a score. A high floor or ceiling effect could make it difficult to measure therapy-induced changes (22, 24).

**Construct validity** was assessed by using Spearman's rank correlation coefficient ($r_S$) to test several predefined hypotheses concerning the relationship between ArmA-S and other baseline measurements. The correlation coefficients were interpreted according to an often-quoted rule of thumb for interpreting the size of a correlation: 0.90–1.00, very high; 0.70–0.90, high; 0.50–0.70, moderate; 0.30–0.50, low; and 0.00–0.30, little or none (25). Since the other outcome measures were considered to cover somewhat different aspects as compared to ArmA-S, we expected to find low to moderate correlations. Specifically, we hypothesized that both of the ArmA-S subscales would have a low correlation with the DASH score; that subscale A would correlate moderately with the MAS composite score; and that subscale B would correlate moderately with the GRT.

**Responsiveness** was assessed as the validity of therapy-induced change in outcome scores, referred to as longitudinal validity. To assess longitudinal validity, we hypothesized that the from pre- to postintervention change in the total score of section A of ArmA-S would have a low correlation with the changes in DASH and GRT and a moderate correlation with the change in MAS. The pre- to postintervention change in the total score on section B of ArmA-S was hypothesized to have a low correlation with the change in DASH and moderate correlation with the change in MAS and GRT. The change from baseline to the 3-month follow-up in outcome measures was calculated with the Wilcoxon signed-rank test.

**Interpretability** was judged from estimates of minimal important change (MIC). MIC was calculated the same two ways as in the psychometric analyses of ArmA (14), using a distribution-based method (26), and further as half the baseline standard deviation for sections A and B as an estimation of MIC. This
approach was applied to the whole study population, as well as to each of the three treatment regimens separately for both analyses. Both methods use parametric assumption and therefore provide only a preliminary indication of interpretability because ArmA-S is an ordinal measure. All data analyses were done with SPSS for MAC (Version 27: SPSS, Chicago, IL, USA).

Results

Study participants

The study sample consisted of 58 patients with debilitating UL spasticity due to SCI (n=31), stroke (n=25), TBI (n=4), or other diagnosis (n=6). Eight patients had undergone spasticity-correcting surgery on both the right and left arms, on different occasions, for a total of 66 interventions. The mean age of the patients was 57 years (range 19–79). The mean time since the injury was 8.1 years (range 1–26). Preoperative allocation to a treatment regimen was based on the residual volitional motor control in the UL and on cognitive ability: 25 patients were assigned to HFR (38%), 30 to LFR (45%), and 11 to NFR (17%). Demographic and clinical characteristics of the study participants are listed in Table 2. Of 66 collected questionnaires, five were excluded because planned surgeries were postponed, resulting in a maximum of 61 questionnaires for analyses. Fifty-one patients completed the questionnaire twice for test-retest reliability; however, three completed questionnaires were excluded for missing answers, leaving 48 questionnaires for the test-retest analyses. The average time range between survey 1 and 2 was 6.7 days (range 4–10 days).

Translation and adaption

Initial forward translation of the ‘tryout’ version of ArmA: In our search for a questionnaire that is sensitive for change in a heterogenic population of patients with neurological injuries, the choice fell on ArmA. To make a preliminary feasibility assessment of ArmA in a Swedish clinical setting, the original English version of the questionnaire was first translated into Swedish by two bilingual clinicians using a forward translation procedure. This first version is referred to as the tryout-ArmA-S. Testing of the tryout-ArmA-S, which was originally developed for patients with unilateral hemiplegia, revealed that patients with bilateral UL motor impairment after SCI were confused by the term the affected arm as they had bilateral UL spasticity. Another confusion arose from the original instructions, which specified that the response option 0 (no difficulty) be selected if the activity is never done. However, this has nothing to do with the patient’s affected/treated arm, causing difficulties in selecting option 0 (no difficulty) versus option 4 (unable to do) and increasing the need for explanation in a face-to-face situation. Patients thought that most questionnaire items were meaningful. After using the tryout-ArmA-S for 18 months in our clinical setting, we decided to proceed with psychometric evaluation despite its shortcomings. We therefore conducted a proper back-translation procedure.

Back-translation procedure: The guide to completion and questionnaire items in ArmA were easily translated from English to Swedish. Item 10 in section B (handle a home telephone) was changed because such phones are rarely used in Sweden nowadays. It was replaced by the item handle your
phone. Some additional minor adjustment was made in the demographic part of ArmA-S: SCI was added as a neurological condition, and information about the caregiver was expanded to include hours and type of assistance (caregiver or professional). To facilitate completion of the questionnaire by patients with bilateral UL motor impairment, the term affected arm in the ArmA-S was clarified by adding the arm that will be, or is treated. The most significant modification in the Swedish version of ArmA was done to minimize the risk of faulty/misleading responses when a specific activity was never done by patients. Misinterpretation could lead to false-negative results if the patient argues the activity was never done before surgery (which equals score 0, no difficulty) even though the true reason is the severely impaired UL and the postsurgery score is 1 (no difficulty) to 4 (maximum difficulty). Thus, although the patient improved after surgery, the scoring indicates the opposite. To help patients select proper responses, the option never done (score 0) was added to ArmA-S, resulting in a six-point Likert scoring system. Further, instead of presenting the response options as digits (0–4), we changed the Likert-scale to verbal statements, describing the degree of difficulty as ranging from no difficulty to unable to perform, which are converted to scores 0–4. Instead of circling a response digit, the respondent is asked to mark with an X the appropriate verbal statement for each activity.

Validity of final ArmA-S

The content validity of final version of ArmA-S was judged to be good based on opinions from both patients and expert clinicians. Further, this version was recognized as having good face validity in the sense of being clear, understandable, and easy to complete. All patients except one (5%) responded that the final version was easy or moderately easy to complete, and all patients thought the questions were moderately to very relevant. With no exceptions, the clinicians responded that the measurement tool would be useful in clinical settings for patients with hemiplegia, but also for other patient groups with neurological injuries. Of the 20 patients who were timed, 10 (50%) completed the questionnaire in less than 10 minutes and 90% in less than 20 minutes. In the analyses of floor or ceiling effects, the baseline score before surgery was used. One (1.6%) of 61 completed questionnaires had the highest possible score (0 points) on section A, one (1.6%) had the highest score (0 points) on section B, and six (9.8%) had the worst possible score (52 points) on section B. Yet, the median (interquartile range) scores for sections A and B were 12 (8–17) and 46 (37–49), respectively. Thus, there were no floor or ceiling effects. The analyses of construct validity revealed great variety in the correlation between ArmA-S section A and B and the other outcome measures (Table 3). The GRT had the highest correlation with section B of the final ArmA-S ($r_S=0.59; p<0.000$), whereas DASH had little or no correlation with sections A and B ($r_S=0.05$, $p=0.75$ for both correlations).

Reliability of the final ArmA-S

The internal consistency of the final ArmA-S version was high, with a Cronbach's alpha coefficient of 0.94 for section A and 0.93 for section B (n=61). Test-retest reliability, analysed for 48 patients, resulting in a quadratic weighted Cohen's kappa coefficient of 0.86 (95% confidence interval [CI], 0.78–0.95) for section A and 0.83 (95% CI, 0.67–1.00) for section B. The responsiveness was analysed in patients who
completed the survey before their spasticity-correcting surgery and 3 months afterward (n=55). As hypothesized, assessment of longitudinal validity revealed little or low correlation between the mean change in the total score on section A and the mean change in all other outcome measures (DASH: $r_s$ 0.2; p=0.32; MAS: $r_s$ 0.2; p=0.14 and GRT: $r_s$ 0.2; p=0.30). The equivalent analysis for section B revealed little or low positive or negative correlation with the other measures (DASH: $r_s$ 0.3; p=0.13; MAS: $r_s$ -0.2; p=0.21 and GRT: $r_s$ -0.2; p=0.001). The analysis of the mean change in final ArmA-S total score from the pre-surgical survey to the 3-month follow-up (Table 4) showed significant increases in both section A and section B (p< 0.001). Eleven patients who reported little or no use of the hand before surgery (section B score, 49–52) had some active use of the hand, as captured by the lower section B score 3 months after surgery (30–48 in this subgroup). Significant improvements were also shown in the mean change in GRT and MAS (p<0.001) but not DASH (p=0.732).

MIC was estimated with a distribution-based method and a criterion-based method (Table 5). For the study population as a whole using a distribution-based method the MIC for section A and B was shown to be 3.2 points and 6.8, respectively. Using a criterion-based method across the whole study population (n=55) resulted in a decrease of 6.1 points in section A and a decrease of 6.5 in section B.

When inspecting the data for analyses of responsiveness (pre- and postsurgical items of sections A and B of ArmA-S), we noted some highly questionable responses to questionnaire items, mainly in section B. Specifically, even though we had added the response option never done to the scoring system, quite a few patients selected the never done option before surgery (no difficulty), but had selected one of the response options no, mild, moderate, severe difficulty, or even unable to do activity after surgery. This indicates an unsuccessful outcome, which was not in accordance with the empirical experiences of patients’ capabilities after the surgical intervention. Thus, the content of the translated version of ArmA still seemed to entail uncertainty. In complementary explorative data analyses, we therefore applied a score transformation to data, based on known characteristics of patients.

**Complementary explorative data analysis:**

In complementary analyses, we compared the original scores with the transformed scores. The scores were transformed as follows. If the pre-surgical score was 0 (never done) and the postsurgical score was 0 (no problem) or between 1 and 4 (various degrees of difficulty), the pre-surgical score was considered an error and was changed to score 4 (unable to do). This transformation required that functional status before surgery clearly indicate that the patient was unable to do the specific activity.

For all test-retest questionnaires, 40% of patients made this error. The results from the corrected analysis substantially lowered the CI for the adjusted scale, resulting in a quadratic weighted kappa coefficient of 0.91 (95% CI 0.85–0.97) for section A and 0.96 (95% CI 0.93–0.99) for section B. Therefore, in the recommended Swedish version, the guidance was clarified and the scale was altered to make it easier to complete the questionnaire correctly and independently and to minimize identified errors without changing the original instructions of the scale. See appendix 2 for the recommended ArmA-S.
A complementary analysis was made in which the participants were split in two sub-cohorts based on diagnosis (SCI n=18 and Stroke n=20). Splitting the cohort resulting in a quadratic weighted Cohen’s kappa coefficient of 0.92 (95% confidence interval [CI], 0.85–0.99) for section A in the SCI group and 0.79 (95% CI, 0.62–0.97) in the stroke group. Corresponding figures for section B was 0.79 (95% CI, 0.51–1.07) and 0.82 (95% CI, 0.67–1.0), respectively. The analysis of the mean change in final ArmA-S total score from pre-intervention to the 3-month follow-up showed significant increases for both groups in both section A and B. When comparing the mean change in final ArmA-S total score between the subgroups a significant difference was demonstrated for section B (p=0.016) in favour of the SCI group, but not for section A (p=0.116).

**Discussion**

This study provides support for the use of ArmA-S to assess active and passive UL functional status in patients with disabling UL spasticity. The majority of the tested hypotheses were confirmed, demonstrating that the ArmA-S has good validity, reliability, and responsiveness in the evaluation of patients with UL spasticity due to neurological conditions, including SCI. Most psychometric properties were in agreement with the original English version of ArmA. In the previously evaluated English and Thai versions of ArmA, section A comprised 7 items (14–16). Based on recommendation by the developer of ArmA, one additional item was added to section A (14). The version used in the present study comprises 8 item in section A, (core range 0–32 points). Thus, there is a discrepancy in the maximum section A score between the current Swedish and the English and Thai versions of ArmA.

The translation and cultural adaptation of ArmA-S to ensure semantic and conceptual equivalence to the original version proceeded without difficulties. The questionnaire was judged by patients and clinicians to have **good content and face validity** as well as **acceptability**. Few missing answers were found (3 questionnaires were excluded from analyses of test-retest reliability and 2 from analyses of responsiveness because of missing answers), indicating a good completeness of responses. Half of the patients completed ArmA-S in less than 10 minutes, which further supports its clinical feasibility and implementability. The somewhat longer completion time for some participants as compared to the versions in English (14) and Thai (16) may be due to differences in the underlying neurological injury among participants in the two studies.

We found that the ArmA-S had no floor or ceiling effects. Although the median score of the section B total score was rather high (47, IQR 37–49), only six patients (9.8%) had the highest possible score (maximum disability) versus 37% of respondents in the original ArmA. In the present study, 38% of the patients were treated with the HFR, suggesting that their active UL function was expected to improve after surgery. The lack of floor or ceiling effects in ArmA-S speaks in favour of the tool in this type of clinical setting. For the six patients who had the maximal score in section B (maximum disability), the spasticity-correcting surgery was aimed to facilitate passive caring activities, such as personal hygiene and dressing. The clinical outcome in the present study showed that patients with little or no active arm and hand function before surgery, as measured by ArmA-S, achieved gains from the intervention. The unique combination of
active and passive activity aspects in ArmA makes the questionnaire useful for assessing improvements in activity and hygiene aspects in a heterogeneous group of patients with disabling UL spasticity.

In assessing the effectiveness of health care interventions, accurate determinations of the MIC is important. In a previous study of patients with chronic stroke (27), Lewek et al. suggested that expectations for changing gait speed be based on baseline gait speed. Thus, for patients with more significant gait impairment after stroke, one should not expect as large a change as for faster walkers. Lewek et al. also noted that although the change in gait speed is seemingly smaller for slower walkers, it still be a ‘real change’. Most importantly, Lewek and al. noted that a single MIC is often indiscriminately applied to all study participants to determine success, despite differences in participants’ potential treatment responses, as we also found. Like Lewek et al., we believe that treatment-induced gains in UL function may be more clinically relevant for patients with more severe functional impairment after neurological injuries. Consequently, different MICs should be applied to patient groups that vary in the degree of disability. However, our sample size is too small to determine MIC accurately and reliably. Moreover, the ordinal character of the ArmA-S hampers the stability definition of MIC across the scale, as well as the proper interpretation of the final results (28). Therefore, we present only a preliminary indication of interpretability for ArmA-S.

We found that ArmA-S has high internal consistency in both section A and section B (0.94 and 0.93, respectively), in line with the previous psychometric investigations of original ArmA (16). The analyses of responsiveness indicate that ArmA-S (in conformity with GRT and MAS) is better for detecting changes due to spasticity-correcting surgery as compared to DASH, which did not capture any significant improvement. This disparity is not surprising, as DASH was developed to assess a wide range of UL problems and not specifically spasticity-related disorders. Further, DASH was designed to assess higher-level function and is therefore likely to show significant floor effects in a neurologically impaired population. This was the case in a previous study investigating the effectiveness of botulinum toxin for patients with UL spasticity(14). Section A of ArmA did reveal significant improvement after treatment with botulinum toxin (p = 0.01), whereas DASH did not (p = 0.92) (14). In DASH, the respondent is asked to report the degree of difficulty in performing various physical activities because of an arm, shoulder, or hand problem, but with no referral to a specific arm. This may lessen the sensitivity to change and has raised concerns about DASH as an outcome measure in patients with disability after stroke (28). On the other hand, our findings support the use of ArmA-S in clinical or research contexts involving patients with UL spasticity. However, one must bear in mind that self-reporting of spasticity-related disability is a challenge, since patients often experience concurrent clonus, rigidity, and neuropathic pain along with the various aspects of spasticity. Discrimination among symptoms may be difficult (29–31). Complementary evaluation of aspects such as body functions and grip ability is recommended to provide a more complete picture of complex disorders after neurological injuries.

As hypothesized, section A of ArmA-S correlated moderately with GRT, as did section B with GRT and MAS, but did not correlate with MAS. In contrast, the original ArmA did correlate with DASH ($r_s 0.63$; p =
This discrepancy may reflect differences in the clinical characteristics of the two study populations.

In the study evaluating the original version of ArmA (14), the majority of participants were stroke survivors. The complementary analyses in the present study in which the study cohort was split in two, demonstrate satisfactory test-retest reliability and responsiveness of the scale when used for individuals with SCI.

Our study had some limitations that must be considered. First, further investigation and larger sample sizes will be required to clarify the internal structure of the ArmA-S. An accurate MIC is yet to be established. Moreover, it remains to be determined whether the MIC differs between groups of patients that vary in the degree of remaining neurological deficit. Although patients and clinicians both found the questionnaire to be feasible and relevant, some questions arose that indicate areas for improvement of the ArmA-S as a stable self-report measure of spasticity-related UL disability.

## Conclusion

The ArmA-S is a valid and reliable measure for assessing passive and active function in patients with UL spasticity. It should help both researchers and clinicians monitor treatment-induced changes in UL function in patients with various degrees of neurological disability. Further validation in larger samples is needed to evaluate the measurement properties of ArmA-S in response to other treatments besides surgery and to determine the MIC for patients with various degrees of UL disability. Future studies should also focus on obtaining population norms for ArmA-S and on psychometric evaluation of the slightly modified and recommended version of ArmA-S.

## List Of Abbreviations

**ADLs**: Activities of daily living

**ArmA**: Arm Activity Measure

**ArmA-S**: Arm Activity Measure Swedish version

**DASH**: Disability of the arm, shoulder and hand

**CARE**: Centre of Advanced Reconstruction of Extremities

**CNS**: Central nervous system

**CI**: Confidence interval

**GRT**: Grasp and release test

**HFR**: High functioning regimen
Declarations

Ethics approval and consent to participate written informed consent was obtained. Confidentiality was maintained in all aspects of participation, and code numbers were used instead of names on all recorded data. The study was approved by the Swedish Ethical Review Authority, Dnr 535-18.

Consent for publication not appliciable

Availability of data and materials the dataset analysed during the current study are available from the corresponding author on reasonable request.

Competing interests the authors declare that they have no competing interests

Funding This study was supported by research grants from The Local Research and Development Board for Gothenburg and Södra Bohuslän and the Swedish state under the agreement between the Swedish government and the county councils (the ALF-agreement, 725241)

Authors’ Contributions All authors provided critical feedback and helped shape the research, analysis and manuscript. TR wrote the manuscript, collected and analyzed the data; JW and LB-K supervised the data analysis, and manuscript with critical revision of the article for important intellectual content. All authors participated in the translation process.

Acknowledgement The authors thank Professor Stephen Ashford for allowing us to adapt the original ArmA to Swedish. We thank all participants in the evaluation of the pre-final version and the final version of ArmA-S. The authors also thank the clinicians on the expert committee and those who provided valuable feedback on the translation and adaptation of ArmA. Finally, we thank Adnan Noor Baloch for statistical guidance.
Authors’ information

Institute of Clinical Sciences, Department of Orthopaedics at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

TR and JW

Institute of Neuroscience and physiology, Department of Health and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

LB-K

Centre for Advanced Reconstruction of Extremities, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden

TR, JW and LB-K

References

1. Voerman GE, Erren-Wolters CV, Fleuren JF, et al. Perceived spasticity in chronic spinal cord injured patients: Associations with psychological factors. Disabil Rehabil. 2010;32(9):775-780.

2. Maynard FM, Karunas RS, Waring WP, 3rd. Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil. 1990;71(8):566-9.

3. Holtz KA, Lipson R, Noonan VK, Kwon BK, Mills PB. Prevalence and effect of problematic spasticity after traumatic spinal cord injury. Arch Phys Med Rehabil. 2017;98(6):1132-8.

4. Wedekind C, Lippert-Grüner M. Long-term outcome in severe traumatic brain injury is significantly influenced by brainstem involvement. Brain Inj. 2005;19(9):681-4.

5. Thibaut A, Chatelle C, Ziegler E, Bruno M-A, Laureys S, Gosseries O. Spasticity after stroke: Physiology, assessment and treatment. Brain Inj. 2013;27(10):1093-105.

6. Zorowitz DR, Gillard JP, Brainin JM. Poststroke spasticity: Sequelae and burden on stroke survivors and caregivers. Neurology. 2013;80(3 Suppl 2):45-52. Neurology.

7. Waljee JF, Chung KC. Surgical Management of spasticity of the thumb and fingers. Hand Clin. 2018;34(4):473-85.

8. Pendleton HM, Schultz-Krohn W. Pedretti’s occupational therapy: practice skills for physical dysfunction. St. Louis, Missouri: Elsevier; 2018.

9. Naghdi S, Ansari NN, Abolhasani H, Mansouri K, Ghotbi N, Hasson S. Electrophysiological evaluation of the Modified Tardieu Scale (MTS) in assessing poststroke wrist flexor spasticity. NeuroRehabilitation. 2014;34(1):177.

10. Sommerfeld KD, Gripenstedt KU, Welmer KA-K. Spasticity after stroke: An overview of prevalence, test instruments, and treatments. Am J Phys Med Rehabil. 2012;91(9):814-20.
11. Ansari NN, Naghdi S, Younesian P, Shayeghan M. Inter- and intrarater reliability of the Modified Modified Ashworth Scale in patients with knee extensor poststroke spasticity. Physiother Theory Practi. 2008;24(3):205-13.
12. Ansari NN, Karimi H, Farahmand F, Naghdi S, Faghihzadeh S. A new biomechanical method for objective measurement of spasticity: A preliminary study. Int J Ther Rehabil. 2007;14(2):63-9.
13. Ashford S, Slade M, Turner-Stokes L. Conceptualisation and development of the arm activity measure (ArmA) for assessment of activity in the hemiparetic arm. Disabil Rehabil. 2013;35(18):1513-8.
14. Ashford S, Turner-Stokes L, Siegert R, Slade M. Initial psychometric evaluation of the Arm Activity Measure (ArmA): a measure of activity in the hemiparetic arm. Clin Rehabil. 2013;27(8):728-40.
15. Ashford S, Siegert RJ, Alexandrescu R. Rasch measurement: the Arm Activity measure (ArmA) passive function sub-scale. Disabil Rehabil. 2016;38(4):384-90.
16. Buntragulpoontaweew M, Euawongyarti P, Wongpakaran T, Ashford S, Rattanamanee S, Khunachiva JJH, et al. Preliminary evaluation of the reliability, validity and feasibility of the arm activity measure–Thai version (ArmA-TH) in cerebrovascular patients with upper limb hemiplegia. Health Qual. Life. 2018;16(1):141.
17. Beaton ED, Bombardier EC, Guillemin EF, Ferraz EMB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000;25(24):3186-91.
18. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206-7.
19. Wuolle KS, Van Doren CL, Thrope GB, Keith MW, Peckham PH. Development of a quantitative hand grasp and release test for patients with tetraplegia using a hand neuroprosthesis. J Hand Surg Am. 1994;19(2):209-18.
20. Hudak P, Amadio PC, Bombardier C, Beaton D, Cole D, Davis A, et al. Development of an upper extremity outcome measure: The DASH (Disabilities of the Arm, Shoulder, and Hand). Am. J. Ind. Medi. 1996;30(3):372-372.
21. Bergfeldt U, Stromberg J, Ramstrom T, Kulbacka-Ortiz K, Reinholdt C. Functional outcomes of spasticity-reducing surgery and rehabilitation at 1-year follow-up in 30 patients. J Hand Surg E. 2020 [cited 2020 Apr] [6p].
22. Terwee CB, Bot SDM, de Boer MR, van Der Windt DAWM, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34-42.
23. Fayers PM, Machin D. Quality of life: the assessment, analysis, and interpretation of patient-reported outcomes. Chichester: Wiley; 2007.
24. Wamper KE, Siervelet IN, Poolman RW, Bhandari M, Haverkamp D. The Harris hip score: Do ceiling effects limit its usefulness in orthopedics?: A systematic review. Acta Orthop. 2010;81(6):703-7.
25. Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. 5ed. Houghton Mifflin College Division; 2003.
26. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;51(6):582-92.

27. Lewek MD, Sykes III R. Minimal Detectable Change for gait speed depends on baseline speed in individuals with chronic stroke. J Neurol Phys Ther. 2019;43(2):122-7.

28. Draak T, de Greef B, Faber C, Merkies I. The minimum clinically important difference: which direction to take. Eur J Neurol. 2019;26(6):850-5.

29. Ibuki A, Bernhardt J. What is spasticity? The discussion continues. Int J Ther Rehabil. 2007;14(9):391-4.

30. Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1-2):2-6.

31. Priebe MM, Sherwood AM, Thornby JI, Kharas NF, Markowski J. Clinical assessment of spasticity in spinal cord injury: A multidimensional problem. Arch Phys Med Rehabil. 1996;77(7):713-6.

**Tables**
### Table 1
Description of inclusion and exclusion criteria for the different treatment regimens.

| Criteria                                                                 | HFR | LFR | NFR |
|--------------------------------------------------------------------------|-----|-----|-----|
| **Inclusion criteria**                                                  |     |     |     |
| Muscle hypertonicity is the primary component of spasticity             | x   | x   | x   |
| The UL spasticity limits ADLs                                          |     |     | x   |
| The patient had nonpharmacologic and/or pharmacologic spasticity       |     |     | x   |
| treatment, with specific recommendations for botulinum toxin injection |     |     | x   |
| The patient has volition motor function in the UL                       |     | x   |     |
| The patient agrees to comply fully with the treatment regimen          |     | (x) |     |
| The patient is motivated to participate in intensive rehabilitation    |     | (x) |     |
| The patient has stable home care/assistance                            |     | (x) |     |
| Functional score* 1                                                     |     |     | x   |
| Functional score* 2                                                     |     |     | x   |
| Functional score* 3                                                     | x   | x   | (x) |
| Functional score* 4                                                     | x   | (x) | (x) |
| The patient must have residual shoulder mobility                       |     |     | x   |
| **Exclusion criteria**                                                  |     |     |     |
| Severe cognitive impairments                                            |     | x   | x   |
| Mild cognitive impairments                                              |     |     | x   |
| Severe contractures that hinder surgical benefit                        |     |     | (x) |

HFR: high-functioning regimen; LFR: low-functioning regimen; NFR: nonfunctioning regimen.

* = Mertens P, S.M., Surgical management of spasticity, in *Upper Motor Neuron Syndrome and Spasticity: Clinical Management and Neurophysiology*, J.G.E. Barnes MP, Editor. 2001, Cambridge University Press: Cambridge. pp. 239–65.
## Table 2
Demographic and clinical characteristics of the study population (n = 66).

| Demographic or Clinical Characteristic | n    | Percentage (%) |
|---------------------------------------|------|----------------|
| Mean age (years) (min-max)             | 57   | (19–79)        |
| Male/ female ratio                     | 44   | (67)/22 (33)   |
| Diagnosis                              |      |                |
| Spinal cord injury                     | 31   | (47)           |
| Stroke                                | 25   | (38)           |
| Traumatic brain injury                 | 4    | (6)            |
| Other                                 | 6    | (9)            |
| Affected arm (right/left)              | 37   | (56%)/29 (44%) |
| Treatment regimen                      |      |                |
| High-functioning regimen               | 25   | (38)           |
| Low-functioning regimen                | 30   | (45)           |
| Nonfunctioning regimen                 | 11   | (17)           |
| Mean test/restest time interval (days)  | 6.7  | (4–10)         |
| Time between injury and baseline years | 8.1  | (1–26)         |

Data is reported as number (%) unless indicated otherwise.

Min: minimum; Max: maximum; other diagnosis: multiple sclerosis, cerebral palsy, spina bifida, Wilson disease.

## Table 3
Association between ArmA-S Sections A and B and the outcome measures GRT, MAS and DASH at baseline, as well as for the change in scores from baseline to the three-month follow-up.

| Outcome measure | Baseline Score | Change in Score |
|-----------------|----------------|-----------------|
|                 | n              | Section A       | Section B       | Section A | Section B |
| Baseline        |                | $r_S$ p         | $r_S$ p         | $r_S$ p   | $r_S$ p   |
| MAS             | 48             | .20 .216        | .25 .120        | .24 .138  | - .20 .209 |
| GRT             | 53             | -.42 .003       | .59 .000        | .15 .302  | -.45 .001  |
| DASH            | 36             | .05 .754        | .05 .754        | .17 .323  | .26 .128   |

3-month follow-up

| Outcome measure | Baseline Score | Change in Score |
|-----------------|----------------|-----------------|
|                 | n              | Section A       | Section B       | Section A | Section B |
| MAS change      | 40             |                |                | .24 .138  | - .20 .209 |
| GRT change      | 48             |                | .15 .302       | -.45 .001 |
| DASH change     | 35             |                | .17 .323       | .26 .128  |

$r_S$: Spearman correlation coefficient; ArmA-S: arm activity measure Swedish version; MAS: modified Ashworth scale; GRT: grasp and release test; DASH: disabilities of the arm, shoulder, and hand.

## Table 4
Changes in outcome measures between baseline and the 3-month follow-up.

| Outcome Measure | n    | Baseline Median (IQR) | 3 months Median (IQR) | Change Median (IQR) | P    |
|-----------------|------|-----------------------|-----------------------|---------------------|------|
| ArmA-S          |      |                       |                       |                     |      |
| Section A Total score | 55   | 12.0 (8–17)           | 5.0 (2–9)             | -6.0 (-1.0 – -10.0) | .000 |
| HFR             | 17   | 12.0 (9.5–15.0)       | 5.0 (2.5–9.0)         | -6.0 (-1.5 – -10)   | .001 |
| LFR             | 29   | 11.0 (6.0–14.0)       | 5.0 (1.0–-7.7)        | -4.0 (-1.0 – -9.7)  | .000 |
| NFR             | 9    | 17.5 (12.7–18.5)      | 8.0 (3.75–--11.2)     | -9.0 (-6.0 – -12.0) | .005 |
| Section B Total score | 55   | 46.0 (37–49)          | 42.0 (20–48)          | -4.0 (-0 – -13.0)   | .000 |
| HFR             | 17   | 37 (29.5–47.0)        | 28.0 (14.0–41.5)      | -9.0 (-4.0 – -19.0) | .000 |
| LFR             | 29   | 46.5 (39.2–48.7)      | 42.5 (25.7–47.7)      | -4.0 (-0.2 – -13.2)| .002 |
| NFR             | 9    | 50.0 (39.0–52.0)      | 50.5 (37.5–52.0)      | 0.0 (0.0 – -1.2)    | .343 |
| GRT             | 48   | 14.5 (0.0–57.5)       | 23.0 (0.0–67.7)       | 10.0 (0.0–11.7)     | .000 |
| MAS             | 40   | 8.0 (2.7–4.0)         | 0.8 (0.2–1.2)         | -2.2 (-1.8 – -3.0)  | .000 |
| DASH 1–21       | 35   | 8.0 (63–101)          | 83.0 (68–101)         | 0.0 (3.0–4.0)       | .732 |

IQR: interquartile range; ArmA-S: arm activity measure Swedish version; HFR: high-functioning regimen; LFR: low-functioning regimen; NFR: nonfunctioning regimen; GRT: grasp and release test; MAS: modified Ashworth scale; DASH: disabilities of the arm, shoulder, and hand.
Table 5
Minimal important change estimated with a criterion-based approach for patients who underwent surgery or a distribution-based approach for patients who underwent surgery and had complete baseline measures.

| Method                      | n   | ArmA-S Section A | n   | ArmA-S Section B |
|-----------------------------|-----|------------------|-----|------------------|
| Criterion-based approach    |     |                  |     |                  |
| Whole group                 | 55  | 6.1              | 55  | 6.5              |
| HFR                         | 17  | 6.2              | 17  | 11.2             |
| LFR                         | 29  | 5.0              | 29  | 5.8              |
| NFR                         | 9   | 8.3/9.1          | 9   | 0.7              |
| Distribution-based approach |     |                  |     |                  |
| Whole group                 | 61  | 3.2              | 61  | 6.8              |
| HFR                         | 21  | 2.6              | 20  | 6.2/6.5          |
| LFR                         | 29  | 3.3              | 28  | 5.2 (4.2*)       |
| NFR                         | 11  | 2.8              | 10  | 9.7 (1.8*)       |

*Score achieved when one outlier was removed.

ArmA-S: Arm Activity Measure Swedish version; HFR: high-functioning regimen; LFR: low-functioning regimen; NFR: nonfunctioning regimen.